VX-407 for Polycystic Kidney Disease
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of the study is to evaluate the pharmacokinetics, safety and tolerability of VX-407 following a single oral dose.
Are You a Good Fit for This Trial?
This trial is for adults with a BMI between 18 and 32, weighing over 50 kg, who have regular bowel movements (1–3 times per day).Inclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- VX-407
Trial Overview
The study tests how the body absorbs, processes, and eliminates a single oral dose of VX-407 labeled with a small amount of radioactive carbon (14C) in people with polycystic kidney disease.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Participants will receive a single oral dose of 14C-VX-407 after an overnight fast of at least 8 hours.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Vertex Pharmaceuticals Incorporated
Lead Sponsor
Dr. David Altshuler
Vertex Pharmaceuticals Incorporated
Chief Medical Officer since 2020
MD, PhD
Dr. Reshma Kewalramani
Vertex Pharmaceuticals Incorporated
Chief Executive Officer since 2020
MD, trained in internal medicine and nephrology
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.